patientresources image

Highlighting Insights From the Marginal Zone Lymphoma Workshop

Data show improvements in overall survival and time to subsequent therapy initiation with darolutamide plus ADT/docetaxel.

Clinicians outline the significance of the MZL Workshop, where a gathering of international experts in the field discussed updates in the disease state.

Thomas Habermann, MD;Julie M. Vose, MD, MBA;James R. Cerhan, MD, PhD;Alexandar Tzankov, MD;Andrew D. Zelenetz, MD, PhD

February 17th 2025

Age Did Not Negatively Impact Response From CAR T-Cell Therapy in R/R LBCL

Clinicians outline the significance of the MZL Workshop, where a gathering of international experts in the field discussed updates in the disease state.

Ariana Pelosci

Navigating Management and Dosing Considerations for Amivantamab in NSCLC

Median PFS and OS were comparable between age groups when CAR T-cell therapy was given as treatment for patients with relapsed/refractory LBCL.

Experts from Washington University in St. Louis discuss trial results and infusion-related reaction management for amivantamab in EGFR-mutated NSCLC.

Daniel Morgensztern, MD;Mary Ellen Flanagan, NP ;Janelle Mann, PharmD, BCOP

February 10th 2025

Venetoclax/Ibrutinib Significantly Improves PFS in Mantle Cell Lymphoma

Experts from Washington University in St. Louis discuss trial results and infusion-related reaction management for amivantamab in EGFR-mutated NSCLC.

Roman Fabbricatore

Forecast on Eliminating Cancer Disparities Looks to Ethnic Enclave Research

The safety profile of ibrutinib/venetoclax in the phase 3 SYMPATICO trial was consistent with the known profiles for each individual agent.

Ariana Pelosci

Darolutamide/ADT Yields Consistent Outcomes Across HSPC Age Subgroups

Scarlett Lin Gomez, MPH, PhD, highlights facts from her research that are impacting cancer disparities and how she is finding ways to improve them.

Related Content

Ben Saylor

Highlighting Insights From the Marginal Zone Lymphoma Workshop

Data show improvements in overall survival and time to subsequent therapy initiation with darolutamide plus ADT/docetaxel.

Thomas Habermann, MD;Julie M. Vose, MD, MBA;James R. Cerhan, MD, PhD;Alexandar Tzankov, MD;Andrew D. Zelenetz, MD, PhD

February 17th 2025

Age Did Not Negatively Impact Response From CAR T-Cell Therapy in R/R LBCL

Clinicians outline the significance of the MZL Workshop, where a gathering of international experts in the field discussed updates in the disease state.

Ariana Pelosci

Navigating Management and Dosing Considerations for Amivantamab in NSCLC

Median PFS and OS were comparable between age groups when CAR T-cell therapy was given as treatment for patients with relapsed/refractory LBCL.

Daniel Morgensztern, MD;Mary Ellen Flanagan, NP ;Janelle Mann, PharmD, BCOP

February 10th 2025